(Circulation. 1997;96:1330-1336.)
© 1997 American Heart Association, Inc.
Articles |
Regression of Left Ventricular Hypertrophy With Captopril Restores Normal Ventricular Action Potential Duration, Dispersion of Refractoriness, and Vulnerability to Inducible Ventricular Fibrillation
From the Cardiovascular Division, The Lankenau Hospital and Medical Research Center, Wynnewood, and Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa.
Correspondence to Seth J. Rials, MD, PhD, Lankenau Medical Office Building East, 100 Lancaster Ave, Suite 556, Wynnewood, PA 19096.
Background Left ventricular hypertrophy (LVH) is associated with multiple cellular electrophysiological abnormalities, susceptibility to ventricular arrhythmias, and an increased risk of sudden death. Several pharmacological therapies have been shown to produce regression of hypertrophy, but the value of regression is unclear. The present study examines whether pharmacological regression of LVH has effects on the susceptibility to ventricular arrhythmia or the cellular electrophysiological abnormalities of LVH.
Methods and Results Rabbits underwent unilateral renal artery banding and contralateral nephrectomy to induce LVH or were placed in the control group. Both groups were studied 3 months later by in vivo and in vitro electrophysiological techniques. Banded rabbits had increased mean arterial pressure, increased left ventricular weight and wall thickness, increased dispersion of refractoriness, and lower ventricular fibrillation thresholds than control rabbits. Action potential duration and cell capacitance were also greater in the banded group. Additional rabbits were treated beginning 3 months after banding with either captopril (5 mg·kg-1·d-1) or vehicle added to their diet for an additional 3 months. These rabbits and age-matched controls were then studied by in vivo and in vitro electrophysiological techniques. In banded rabbits that received vehicle and were studied 6 months after banding, increased dispersion of refractoriness, a lower ventricular fibrillation threshold, and action potential prolongation persisted and were unchanged from animals studied 3 months after banding. Captopril, started 3 months after banding, caused regression of hypertrophy and normalization of the in vivo and in vitro electrophysiological abnormalities. Addition of captopril to the tissue bath during in vitro electrophysiological study showed no effect on cells from control or banded rabbits.
Conclusions Pharmacological regression of LVH with captopril normalizes the in vivo and in vitro electrophysiological abnormalities of ventricular hypertrophy and reduces the vulnerability to ventricular fibrillation in a renovascular model of LVH.
Key Words: hypertrophy • captopril • ventricles • electrophysiology
This article has been cited by other articles:
 |
|
 |
|
  D. Guo, L. Young, C. Patel, Z. Jiao, Y. Wu, T. Liu, P. R. Kowey, and G.-X. Yan Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H97 - H104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rivard, P. Paradis, M. Nemer, and C. Fiset Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization Cardiovasc Res, April 1, 2008; 78(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gordon, I. M. Lozinskaya, Z. Lin, S. F. Semus, F. E. Blaney, R. N. Willette, and X. Xu 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels Mol. Pharmacol., March 1, 2008; 73(3): 639 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salles, S. Leocadio, K. Bloch, A. R. Nogueira, and E. Muxfeldt Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension Hypertension, November 1, 2005; 46(5): 1207 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Schreiner, K. Kelemen, J. Zehelein, R. Becker, J. C. Senges, A. Bauer, F. Voss, P. Kraft, H. A. Katus, and W. Schoels Biventricular hypertrophy in dogs with chronic AV block: effects of cyclosporin A on morphology and electrophysiology Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2891 - H2898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Botchway, M. A. Turner, D. J. Sheridan, N. A. Flores, and C. H. Fry Electrophysiological effects accompanying regression of left ventricular hypertrophy Cardiovasc Res, December 1, 2003; 60(3): 510 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peschar, K. Vernooy, W. Y.R Vanagt, R. S Reneman, M. A Vos, and F. W Prinzen Absence of reverse electrical remodeling during regression of volume overload hypertrophy in canine ventricles Cardiovasc Res, June 1, 2003; 58(3): 510 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, J. J. Salata, J. Wang, Y. Wu, G.-X. Yan, T. Liu, R. A. Marinchak, and P. R. Kowey Increasing IKs corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H664 - H670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chouabe, J. Amsellem, L. Espinosa, P. Ribaux, S. Blaineau, P. Megas, and R. Bonvallet Reversibility of electrophysiological changes induced by chronic high-altitude hypoxia in adult rat heart Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1452 - H1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-X. Yan, S. J. Rials, Y. Wu, T. Liu, X. Xu, R. A. Marinchak, and P. R. Kowey Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1968 - H1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, S. J. Rials, Y. Wu, J. J. Salata, T. Liu, D. B. Bharucha, R. A. Marinchak, and P. R. Kowey Left Ventricular Hypertrophy Decreases Slowly but Not Rapidly Activating Delayed Rectifier Potassium Currents of Epicardial and Endocardial Myocytes in Rabbits Circulation, March 20, 2001; 103(11): 1585 - 1590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Kowey, G.-X. Yan, and X. Xu Familial hypertrophic cardiomyopathy: cornering the rat Cardiovasc Res, August 1, 2000; 47(2): 210 - 211. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]
|
|
|
|
 |
|
 X. Xu, S. J. Rials, Y. Wu, T. Liu, R. A. Marinchak, and P. R. Kowey Effects of Captopril Treatment of Renovascular Hypertension on beta -Adrenergic Modulation of L-Type Ca2+ Current J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 196 - 200. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Rials, X. Xu, Y. Wu, R. A. Marinchak, and P. R. Kowey Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1216 - H1224. [Abstract] [Full Text] [PDF]
|
|